针对17β-基类固醇脱酶7型抑制剂的合成和表征
Jean-Yves Sancéau1, René Maltais1, Ming Zhou2
1Organic Synthesis Service, CHU de Québec Research Center-Université Laval, Québec, QC G1V 4G2, Canada; Endocrinology and Nephrology Unit, CHU de Québec Research Center-Université Laval, Québec, QC G1V 4G2, Canada.
概括
新的碳酸衍生物被合成并评估为17β-基固醇脱酶7型 (17β-HSD7) 的抑制剂. 化合物4具有C17-spiranicE环,表现出对17β-HSD7的优越抑制活性,为荷尔蒙依赖癌症治疗提供了一个有前途的途径.
科学领域:
- 药用化学 医学化学
- 酶抑制可以抑制酶.
- 激素依赖的癌症 激素依赖的癌症
背景情况:
- 雌激素 (E2) 和二 (DHT) 等性类固醇激素与激素依赖性癌症有关.
- 17β-hydroxysteroid脱酶类型7 (17β-HSD7) 是一个调节E2和DHT水平的关键酶.
- 向17β-HSD7提供了减少E2和增加DHT的双重方法,使其成为乳腺癌潜在的治疗点.
研究的目的:
- 合成和描述新型碳酸衍生物作为潜在的17β-HSD7抑制剂.
- 评估这些新型化合物对17β-HSD7.7的体外抑制活性.
- 为了比较不同结构修改对17β-HSD7抑制的有效性.
主要方法:
- 基于4-aza-5α-androstane核的新型碳酸衍生物 (化合物3和4) 的化学合成.
- 合成化合物的分子特征.
- 试验室酶分析测试以确定对17β-HSD7介导的雌激素 (E1) 转化为雌激醇 (E2) 的抑制活性 (IC50值).
主要成果:
- 这两种新型碳酸衍生物 (3和4) 在体外抑制了17β-HSD7.
- 与化合物3 (IC50 = 900 nM) 相比,含有 (17R) - 螺旋碳酸盐的化合物4具有显著更高的抑制功效 (IC50 = 63 nM).
- 化合物4比化合物3强14倍,其活性与参考抑制剂1 (IC50 = 111 nM) 相似,具有修改的疏水性侧链呈现.
结论:
- 引入 (17R) - 螺旋碳酸盐部分是加强17β-HSD7抑制的更有效的策略,而不是用氧取代C-2甲基烯.
- 新型碳酸衍生物,特别是化合物4,显示出作为乳腺癌治疗的17β-HSD7抑制剂的有前途潜力.
- 包括C17-spiranic E环在内的结构修改可以在不影响疗效的情况下优化抑制活性.
相关概念视频
Transducer Mechanism: Nuclear Receptors
1.3K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.3K
Oxidation of Alkenes: Syn Dihydroxylation with Osmium Tetraoxide
10.1K
Alkenes are converted to 1,2-diols or glycols through a process called dihydroxylation. It involves the addition of two hydroxyl groups across the double bond with two different stereochemical approaches, namely anti and syn. Dihydroxylation using osmium tetroxide progresses with syn stereochemistry.
10.1K
Antihypertensive Drugs: Thiazide-Class Diuretics
611
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
611
Prodrugs
2.6K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
2.6K
Drug Metabolism: Phase II Reactions
3.8K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.8K
Drug Biotransformation: Overview
2.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.4K


